RCS - Ondine Biomedical - ICU Study Accepted for Publication

Ondine BiomedicalAnnouncement

Today 07:10

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH6148Za&default-theme=true

RNS Number : 6148Z  Ondine Biomedical Inc.  08 April 2026

8 April 2026

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine Biomedical and Royal Columbian Hospital Foundation Announce Major
Research Milestone: First-of-its-Kind ICU Study Accepted by 'Journal of
Critical Care'

Ondine Biomedical Inc. ("Ondine") and Royal Columbian Hospital Foundation
("RCHF") are pleased to announce that the pilot study evaluating nasal
photodisinfection in an intensive care unit ("ICU") setting has been accepted
for publication in the Journal of Critical Care, a leading peer-reviewed
journal in intensive care medicine.

The manuscript, titled "Suppression of Microbial Burden to Reduce Pneumonia in
Critical Illness: the SMURF Feasibility Pilot Study," reports on the
first-ever deployment of nasal photodisinfection therapy in critically ill
patients. The study was conducted by RCHF's Advancing Innovation in Medicine
("AIM") Research Team, with support from Royal Columbian Hospital clinical
staff.

This study represents an early clinical evaluation of nasal photodisinfection
in the ICU, extending its application beyond surgical settings. The findings
contribute to a growing body of evidence supporting this non-antibiotic
approach to reducing microbial burden in high-risk patient populations.

Carolyn Cross, CEO, Ondine Biomedical stated:

"We are grateful to the AIM research team and clinical staff for their
tremendous support, and in particular to Dr. Steven Reynolds, Dr. Elizabeth
Rohrs and Jessica Wittmann for their invaluable expertise and commitment. We
would also like to acknowledge Royal Columbian Hospital Foundation, and the
support of Ralph Turfus and the Foundation's President & CEO Jeff Norris,
who helped establish the funding and innovation infrastructure that made this
work possible.

"Evaluating nasal photodisinfection in a critical care setting represents an
important step in extending its use beyond surgical applications. Infection
remains a significant risk for critically ill patients, particularly in the
context of rising antimicrobial resistance, and approaches that can reduce
microbial burden without relying on antibiotics may play an important role in
supporting patient safety in the ICU."

Hospitals today are confronted by a dual challenge: the diminishing
effectiveness of standard antibiotic treatments due to rising resistance among
common pathogens, and ongoing capacity constraints driven in part by
healthcare-associated infections ("HAIs"), which contribute to prolonged ICU
stays and increased resource utilisation. By evaluating a non-antibiotic
approach to reducing microbial burden, the AIM team is exploring a strategy to
address a root cause of these infections before they develop, with the
potential to support improved patient flow and more efficient use of critical
care resources.

The full findings of the study, including additional clinical and economic
analyses, are expected to be available following online publication in the
Journal of Critical Care.

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via 5654 & Company

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                               +44 (0)20 7418 8900

 5654 & Company (Financial PR and IR Adviser)                ondinebiomedical@5654.co.uk
 Matthew Neal, Chris Gardner, Melissa Gardiner               +44 0791 7800 011

                                                             +44 0775 7697 357

 

 

About the Royal Columbian Hospital Foundation (RCHF) and Advancing Innovation
in Medicine Division

As BC's most comprehensive critical care hospital, one in three British
Columbians rely on Royal Columbian Hospital (RCH). It is the only hospital in
BC with trauma, cardiac, neurosciences, high-risk obstetrics and neonatal
intensive care on one site. RCH looks after some of the most seriously ill and
injured patients in B.C.

Since 1978, donors to Royal Columbian Hospital Foundation have helped fund
priority equipment needs, facility enhancements, research, education and
innovation at Royal Columbian Hospital.

As part of Royal Columbian Hospital Foundation, the AIM Institute is a social
enterprise that partners with innovative health-tech companies, providing
clinical insights grounded in deep expertise, alongside clinical trial design
and execution. Find out more: www.rchfoundation.com/aim
(https://rchfoundation.com/aim-institute/)

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved for nasal decolonisation in Canada, Australia, Mexico and several
other countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUWRNRNVUSRRR



            Copyright 2019 Regulatory News Service, all rights reserved